Table 2 Mechanism and clinical trial phase of drugs against EZH2
From: EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
Mechanism of action | Name | Specific for EZH2 | Status | Ref |
|---|---|---|---|---|
SAH hydrolase inhibitors | DZnep | No | Pre-clinical | [92] |
SAM-competitive inhibitors | Tazemetostat | Yes | Phase II | [93] |
GSK126 (GSK2816126) | Yes | Phase I | [94] | |
SHR2554 | Yes | Phase I | [76] | |
Interfering the interaction between EZH2 and EED | EED226 (MAK683) | Yes | Phase I | [77] |
Promoting EZH2 degradation | Sorafenib | No | FDA approval | [79] |